OAC
MLTX icon

OMERS Administration Corp’s MoonLake Immunotherapeutics MLTX Stock Holding History

OMERS Administration Corp’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,247
Closed -$513K – 459
2022
Q1 		$513K Buy
+46,247
New +$460K 0.01% 135
2021
Q1 		– Sell
-10,000
Closed -$108K – 427
2020
Q4 		$108K Buy
+10,000
New +$106K ﹤0.01% 239

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OMERS Administration Corp's MLTX Position: Q2 2022 in Review

OMERS Administration Corp sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 46,247 shares — an estimated $513K sold.

OMERS Administration Corp first reported a position in MLTX in Q4 2020 and held it in 2 quarters. The position peaked at $513K in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

  • OMERS Administration Corp reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • OMERS Administration Corp sold 46,247 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $513K.
  • OMERS Administration Corp first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 2 quarters.
  • OMERS Administration Corp's MoonLake Immunotherapeutics position peaked at $513K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on OMERS Administration Corp's 13F filing for Q2 2022, filed 12 Aug 2022.